As of 2025-08-18, the EV/EBITDA ratio of Turning Point Therapeutics Inc (TPTX) is -10.23. EV/EBITDA ratio is calculated by dividing the enterprise value by the TTM EBITDA. TPTX's latest enterprise value is 3,484.99 mil USD. TPTX's TTM EBITDA according to its financial statements is -340.81 mil USD. Dividing these 2 quantities gives us the above TPTX EV/EBITDA ratio.
Note: valuation result may not be accurate due to the company's negative EBITDA.
| Range | Selected | |
| Trailing P/E multiples | 11.1x - 14.1x | 13.2x |
| Forward P/E multiples | 13.2x - 33.3x | 17.0x |
| Fair Price | (85.01) - (90.91) | (98.12) |
| Upside | -211.8% - -219.6% | -229.1% |
| Date | EV/EBITDA |